These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 15647695)

  • 1. Use of recombinant human growth hormone in HIV-associated lipodystrophy.
    Burgess E; Wanke C
    Curr Opin Infect Dis; 2005 Feb; 18(1):17-24. PubMed ID: 15647695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human growth hormone therapy in HIV-associated wasting and visceral adiposity.
    Yin MT; Glesby MJ
    Expert Rev Anti Infect Ther; 2005 Oct; 3(5):727-38. PubMed ID: 16207164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human growth hormone: rationale for use in the treatment of HIV-associated lipodystrophy.
    Benedini S; Terruzzi I; Lazzarin A; Luzi L
    BioDrugs; 2008; 22(2):101-12. PubMed ID: 18345707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial.
    Koutkia P; Canavan B; Breu J; Torriani M; Kissko J; Grinspoon S
    JAMA; 2004 Jul; 292(2):210-8. PubMed ID: 15249570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials.
    Sivakumar T; Mechanic O; Fehmie DA; Paul B
    HIV Med; 2011 Sep; 12(8):453-62. PubMed ID: 21265979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.
    Falutz J; Potvin D; Mamputu JC; Assaad H; Zoltowska M; Michaud SE; Berger D; Somero M; Moyle G; Brown S; Martorell C; Turner R; Grinspoon S
    J Acquir Immune Defic Syndr; 2010 Mar; 53(3):311-22. PubMed ID: 20101189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic therapy for HIV-associated lipodystrophy.
    Benavides S; Nahata MC
    Ann Pharmacother; 2004 Mar; 38(3):448-57. PubMed ID: 14755064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth hormone and HIV infection: contribution to disease manifestations and clinical implications.
    Falutz J
    Best Pract Res Clin Endocrinol Metab; 2011 Jun; 25(3):517-29. PubMed ID: 21663844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spotlight on tesamorelin in HIV-associated lipodystrophy.
    Dhillon S
    BioDrugs; 2011 Dec; 25(6):405-8. PubMed ID: 22050344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy.
    Dhillon S
    Drugs; 2011 May; 71(8):1071-91. PubMed ID: 21668043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth hormone-releasing factor agonists for the treatment of HIV-associated lipodystrophy.
    Hu M; Tomlinson B
    Curr Opin Investig Drugs; 2010 Oct; 11(10):1143-50. PubMed ID: 20872317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of altered body composition in HIV-associated lipodystrophy: comparison of rosiglitazone, pravastatin, and recombinant human growth hormone.
    Macallan DC; Baldwin C; Mandalia S; Pandol-Kaljevic V; Higgins N; Grundy A; Moyle GJ
    HIV Clin Trials; 2008; 9(4):254-68. PubMed ID: 18753120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, open-label study to compare the effects of two different doses of recombinant human growth hormone on fat reduction and fasting metabolic parameters in HIV-1-infected patients with lipodystrophy.
    Bickel M; Zangos S; Jacobi V; Lutz T; Knecht G; Goebel F; Staszewski S; Klauke S
    HIV Med; 2006 Sep; 7(6):397-403. PubMed ID: 16903985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose growth hormone and human immunodeficiency virus-associated lipodystrophy syndrome: a pilot study.
    Andersen O; Haugaard SB; Flyvbjerg A; Andersen UB; Ørskov H; Madsbad S; Nielsen JO; Iversen J
    Eur J Clin Invest; 2004 Aug; 34(8):561-8. PubMed ID: 15305891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy.
    Spooner LM; Olin JL
    Ann Pharmacother; 2012 Feb; 46(2):240-7. PubMed ID: 22298602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term high-physiological-dose growth hormone reduces intra-abdominal fat in HIV-infected patients with a neutral effect on glucose metabolism.
    Hansen BR; Haugaard SB; Jensen FK; Jensen JE; Andresen L; Iversen J; Andersen O
    HIV Med; 2010 Apr; 11(4):266-75. PubMed ID: 20002779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12 week induction and 24-week maintenance therapy.
    Grunfeld C; Thompson M; Brown SJ; Richmond G; Lee D; Muurahainen N; Kotler DP;
    J Acquir Immune Defic Syndr; 2007 Jul; 45(3):286-97. PubMed ID: 17592343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.
    Falutz J; Allas S; Mamputu JC; Potvin D; Kotler D; Somero M; Berger D; Brown S; Richmond G; Fessel J; Turner R; Grinspoon S
    AIDS; 2008 Sep; 22(14):1719-28. PubMed ID: 18690162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation.
    Falutz J; Allas S; Kotler D; Thompson M; Koutkia P; Albu J; Trottier B; Routy JP; Cote P; Abribat T; Grinspoon S
    AIDS; 2005 Aug; 19(12):1279-87. PubMed ID: 16052083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.
    Falutz J; Mamputu JC; Potvin D; Moyle G; Soulban G; Loughrey H; Marsolais C; Turner R; Grinspoon S
    J Clin Endocrinol Metab; 2010 Sep; 95(9):4291-304. PubMed ID: 20554713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.